Translational andrology and urology最新文献

{"title":"Machine learning based on automated 3D radiomics features to classify prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL.","authors":"Yunxun Liu, Jiejun Wu, Xinmiao Ni, Qingyuan Zheng, Jingsong Wang, Hao Shen, Lei Wang, Rui Yang, Xiaodong Weng","doi":"10.21037/tau-2024-731","DOIUrl":"https://doi.org/10.21037/tau-2024-731","url":null,"abstract":"<p><strong>Background: </strong>It can be difficult to decide clinically whether males with prostate-specific antigen (PSA) levels between 4 and 10 ng/mL should be suggested for a biopsy. This study aimed to develop a fully-automated magnetic resonance imaging (MRI) based prediction model for patients with PSA levels of 4-10 ng/mL to predict prostate cancer (PCa) preoperatively and reduce unnecessary biopsies.</p><p><strong>Methods: </strong>A retrospective study of 574 patients with PSA of 4-10 ng/mL was conducted, split into training (n=434) and testing (n=108) groups. A no-new-Net (nnU-net) model was trained for three-dimensional (3D) prostate segmentation on T2-weighted fast spin echo (T2FSE) MRI sequences and 1,595 radiomics features were extracted with PyRadiomics. There were 113 machine learning approaches compared to construct a radiomics model after features selection. The diagnostic performance of the model was compared with PSA and PSA density (PSAD).</p><p><strong>Results: </strong>The nnU-net model achieved relatively higher accuracy of segmentation for the prostate region in various datasets. The average dice was 95.33%, the average relative volume error (RVE) was 1.57%, and the average 95% Hausdorff distance (HD95) value was 2.73 mm. The radiomics model [area under the curve (AUC): 0.938; 95% confidence interval (CI): 0.916-0.960] shows superior accuracy to PSA (AUC: 0.542; 95% CI: 0.474-0.611) and PSAD (AUC: 0.718; 95% CI: 0.659-0.777) in predicting PCa (P<0.05).</p><p><strong>Conclusions: </strong>The automated 3D radiomics model holds the potential to reduce unnecessary biopsies and aid urologists in managing patients with PSA levels of 4-10 ng/mL.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 4","pages":"1025-1035"},"PeriodicalIF":1.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic resonance imaging for computer-assisted device guidance in transperineal prostate biopsy and cryoablation.","authors":"Thomas Lilieholm, Walter F Block, Erica Knavel Koepsel","doi":"10.21037/tau-2024-635","DOIUrl":"https://doi.org/10.21037/tau-2024-635","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Magnetic resonance imaging (MRI) guided, minimally invasive transperineal interventions have been shown to produce positive clinical outcomes, specifically regarding prostate biopsy and cryoablation of prostate cancer. Many vendors, however, do not provide guidance to clinicians as to how their devices, biopsy needles and cryoprobes should be inserted during procedures. As a result, many leading research institutions have developed in-house solutions for needle insertion guidance. Institutions with less research and engineering support may find the development of their own in-house solutions infeasible, leading to a gap in clinical practice. Our purpose was to develop a replicable toolset using minimal hardware and software to facilitate MRI-guided prostate biopsy and cryoablation. The toolset was validated first in a series of phantom trials, then in a clinical cohort of 24 patients from a single institution.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study utilized a grid-like rigid trajectory guide coupled with custom software to simulate in phantoms, and then perform on patients, prostate-focused interventional procedures using a closed bore General Electric 450W scanner. Only standard imaging sequences were employed, allowing this work to be generalizable between different scanners with no additional setup. Interventionalists imported the coordinates of the targets in the prostate and the 3 saline-filled fiducial markers on the grid into custom software, which then identified the grid hole and depth of insertion necessary to drive needles to the targeted points. In phantom trials, the targeting error of each insertion was logged. All patients enrolled in the study were men over the age of 50 years with either biopsy-confirmed prostate cancer with magnetic resonance (MR)-visible lesions or prostatic fluid collection. Each patient was reviewed by a multidisciplinary focal prostate therapy team consisting of one interventional radiologist and two urologists. Patients were seen in interventional radiology and urology clinics. During each procedure the number of needle insertions and adjustments was tracked to better evaluate accuracy in clinical practice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The targeting grid and software allowed rapid, repeatable needle insertions with a mean error of 1.05 mm and a standard deviation 0.38 mm. Across 24 prostate-focused procedures (9 biopsies, 14 cryoablations, 1 fluid aspiration), the tools guided interventionalists on their initial insertion of biopsy needles or cryoprobes. In an average procedure, 81.8% of the inserted needles required no adjustment from their first insertion. All procedures achieved technical success during the intervention, satisfying the leading clinician's standards for biopsy sample collection and/or ablation coverage.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Phantom and patient trials found that the proposed tools and techniques enabled clinicians to quickly and accurat","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 4","pages":"928-939"},"PeriodicalIF":1.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and validation of glycosyltransferase-related gene signatures to predict prognosis and immunological characteristics of renal clear cell carcinoma.","authors":"Min Ma, Ting Huang, Zekun Xu, Min Xu","doi":"10.21037/tau-2025-21","DOIUrl":"https://doi.org/10.21037/tau-2025-21","url":null,"abstract":"<p><strong>Background: </strong>Clear cell renal cell carcinoma (ccRCC) is more prone to metastasis and is associated with a poorer prognosis than renal cell carcinoma (RCC). Numerous studies have reported a correlation between the expression of glycosyltransferases (GTs)-related genes and tumor. We aimed to establish a risk model based on GTs-related genes in ccRCC, and explore their correlation with tumor immune characteristics and treatment sensitivity.</p><p><strong>Methods: </strong>The messenger ribonucleic acid (mRNA) expression data were retrieved from The Cancer Genome Atlas (TCGA). Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression were used to construct prognostic model. Kaplan-Meier survival and receiver operating characteristic (ROC) curves were used to evaluate the accuracy of the model. Calibration curves and decision curve analysis (DCA) curves were used to evaluate the model. The quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect the expression of the signature genes in human renal epithelial cells and human renal cancer cells. The ESTIMATE algorithm was used to estimate the immune scores in tumor tissues. Single-sample gene set enrichment analysis (ssGSEA) was used to evaluate the immune microenvironment. Tumor Immune Dysfunction and Exclusion (TIDE) and immune checkpoint analysis were used to assess the benefit of immunotherapy. Tumor mutational burden (TMB) analysis was used to calculate the frequency of gene mutations. Susceptibility to anticancer drugs in different risk groups was also analyzed.</p><p><strong>Results: </strong>Four signature genes were identified as potential biomarkers, and the prognostic model demonstrated good predictive performance. qRT-PCR results were consistent with the actual predictions, confirming the credibility of the signature genes. The high- and low-risk groups exhibited different abundance and enrichment of immune cell infiltration. The high-risk group exhibited a higher frequency of tumor mutations than the low-risk group. TIDE and drug sensitivity analysis results demonstrated appropriate treatments for different risk groups, respectively.</p><p><strong>Conclusions: </strong>A prognostic model for ccRCC with four signature genes, was established and demonstrated high predictive performance. Four signature genes provided a foundation for studying the mechanism of GTs-related genes in ccRCC progression.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 4","pages":"986-1004"},"PeriodicalIF":1.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-dimensional measurement and analysis of the compressor urethrae and urethra in postpartum women.","authors":"Yankun Feng, Guibing He, Shihan Fu, Yangzhi Hu, Qiben Wang, Lidong Zhai, Rui Yu","doi":"10.21037/tau-2024-695","DOIUrl":"https://doi.org/10.21037/tau-2024-695","url":null,"abstract":"<p><strong>Background: </strong>The position and lines of the compressor urethrae, as well as the different segments and morphological characteristics of the compressor urethrae and urethra have not been systematically characterized. This study thus aimed to quantify the lines, thickness, volume, surface area, and position of the compressor urethrae, as well as the thickness, volume, and surface area in the upper, middle, and lower urethra, in postpartum females via three-dimensional (3D) measurement and analysis methods.</p><p><strong>Methods: </strong>This retrospective study included a total of 90 postpartum women. The 3D models of compressor urethrae and urethra were constructed based on the imaging pictures of these women. The indicators that were analyzed in a 3D plane included volume, surface area, thickness, and diameter lines of the compressor urethrae; the ratio of the compressor urethrae length (CUL) to the urethral length (UL); the distance between the compressor urethrae and the pubic symphysis; the volume, surface area, and thickness of urethra and its different segments; the UL; and the urethral inclination angle (UIA). These indicators were compared between a postpartum-stress urinary incontinence (SUI) group and a control group. Differences in indicators between the segments of urethra were compared. The relationship between related indicators of the compressor urethrae and of the urethra with age was determined.</p><p><strong>Results: </strong>The length, width, and volume of the compressor urethrae in the control group were 23.24±3.29 mm, 24.61±3.79 mm, and 1.47±0.49 cm³, respectively. The upper, middle and lower regions of the urethral volume in the control group were 2.58±0.59, 2.10±0.32, and 0.84±0.37 cm³, respectively. The volume and thickness of the compressor urethrae, the CUL, and volume of the upper and middle regions of the urethra in the control group were significantly larger than those in the SUI group (P=0.002, P=0.02, P=0.01, P=0.003, and P<0.001, respectively). The volume and surface area of middle urethra were significantly larger than those of the lower urethra (P<0.001 and P<0.001, respectively). The compressor urethrae volume (r=-0.506; P=0.004), compressor urethrae surface area (r=-0.523; P=0.003), middle urethral volume (r=-0.403; P=0.03), and middle urethral thickness (r=-0.629; P<0.001) were negatively correlated with age.</p><p><strong>Conclusions: </strong>This study provides reference criteria for the volume, thickness, and surface area of different portions of the compressor urethrae and urethra. The upper and middle urethra may be particularly significant to female urinary continence. Meanwhile, strengthening of the compressor urethrae might help treat female urinary continence.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 4","pages":"1036-1048"},"PeriodicalIF":1.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vibegron for overactive bladder in men with benign prostatic hyperplasia/obstruction: insights from the COURAGE trial.","authors":"Hossein Saadat, Naeem Bhojani, Dean Elterman, Bilal Chughtai","doi":"10.21037/tau-2024-759","DOIUrl":"https://doi.org/10.21037/tau-2024-759","url":null,"abstract":"","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 4","pages":"888-892"},"PeriodicalIF":1.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The patients have spoken: how does enfortumab vedotin impact quality of life?","authors":"Jason R Brown","doi":"10.21037/tau-2025-45","DOIUrl":"https://doi.org/10.21037/tau-2025-45","url":null,"abstract":"","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 4","pages":"868-871"},"PeriodicalIF":1.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inverted V-shaped association between atherogenic index of plasma and kidney stone risk: results from NHANES 2011-2018.","authors":"Mengyu Zhang, Jiankang Zhang, Yunzhi Cui, Zengshu Xing","doi":"10.21037/tau-24-605","DOIUrl":"https://doi.org/10.21037/tau-24-605","url":null,"abstract":"<p><strong>Background: </strong>Serum lipids are strongly associated with kidney stones. The atherogenic index of plasma (AIP) can be used to quantify lipid levels. However, the nonlinear relationship between AIP and kidney stones is unknown. Hence, our objective was to investigate the nonlinear association between AIP and kidney stones and to identify potential threshold effects and subgroup-specific associations.</p><p><strong>Methods: </strong>We conducted a cross-sectional study involving individuals aged 18 and above from the National Health and Nutrition Examination Survey (NHANES) dataset between 2011 and 2018. Overall, 9,366 subjects were enrolled in this research. AIP was determined using log10 [triglycerides (TG)/high-density lipoprotein cholesterol (HDL-C)]. The outcome variable was a self-reported history of kidney stones. Multifactorial logistic regression, subgroup analyses, interaction tests, restricted cubic spline (RCS) modeling, and threshold effect evaluations were used to investigate the connection between AIP and kidney stones.</p><p><strong>Results: </strong>Data from 9,366 participants were analyzed, and 936 (9.99%) subjects with kidney stones were identified. After adjusting for all covariates, logistic regression analysis demonstrated a meaningful positive association between AIP and the renal calculi, with a 1.33-fold rise in the prevalence of renal calculi for every 1-unit raise in AIP in participants [odds ratio (OR) 1.33, 95% confidence interval (CI): 1.06, 1.68]. RCS analysis showed an inverted V-shaped nonlinear association between AIP and kidney stones. Among participants with AIP <0, a notable correlation was observed between elevated AIP levels and a heightened risk of renal calculi.</p><p><strong>Conclusions: </strong>AIP correlates with kidney stones in an inverted V-shape, suggesting the potential of AIP in predicting kidney stones. However, this relationship is limited, and further studies are needed to validate it.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 4","pages":"953-963"},"PeriodicalIF":1.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness of rezvilutamide plus androgen deprivation therapy in patients with low-volume, metastatic hormone-sensitive prostate cancer: a retrospective multicenter study.","authors":"Shaoxi Niu, Dan Xia, Baojun Wang, Xiaotian Wang, Qifu Zhang, Jiangping Wang, Xin Jin, Lijun Mao, Yashi Ruan, Hui Wang, Fanghu Sun, Zheng Cai, Yifan Chen, Tao Zeng, Xuebao Xiang, Ziyang Qiang, Jun Zhang, Yugang Liu, Peijie Chen, Jun Li, Xu Zhang, Liping Wang, Zhou Ying, Du Wang, Chaoyu Lin, Ting He","doi":"10.21037/tau-2025-239","DOIUrl":"https://doi.org/10.21037/tau-2025-239","url":null,"abstract":"<p><strong>Background: </strong>The CHART study established the combination of rezvilutamide and androgen deprivation therapy (ADT) as a standard treatment for patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC). However, the therapeutic outcomes of this regimen in patients with low-volume mHSPC remain insufficiently defined. This study thus aimed to assess the real-world effectiveness of rezvilutamide combined with ADT in the treatment of low-volume mHSPC.</p><p><strong>Methods: </strong>This multicenter, noninterventional, observational study was conducted in China and included adult patients diagnosed with low-volume mHSPC who were treated with rezvilutamide in combination with ADT as determined by the investigator. The study assessed prostate-specific antigen (PSA) responses at multiple time points (3, 6, 9, and 12 months), including a PSA decline ≥50% (PSA50), a PSA decline ≥90% (PSA90), and a PSA level <0.2 ng/mL (undetectable PSA). Subgroup analyses of PSA responses were conducted according to baseline characteristics, including age, Eastern Cooperative Oncology Group performance status (ECOG PS), and Gleason score.</p><p><strong>Results: </strong>Between August 29, 2023 and December 31, 2024, a total of 257 patients were enrolled in the study. The median age was 73 years [interquartile range (IQR), 68-77 years], and the median baseline PSA level was 38 ng/mL (IQR, 7-100 ng/mL). PSA responses were observed as early as 3 months after initiating rezvilutamide treatment, with 88% [176/199; 95% exact confidence interval (CI): 83-93%] achieving PSA50, 75% (149/199; 95% exact CI: 68-81%) achieving PSA90, and 54% (108/199; 95% exact CI: 47-61%) achieving undetectable PSA levels. These responses further improved at subsequent time points (6, 9, and 12 months). By 12 months, 100% (12/12; 95% exact CI: 74-100%) achieved PSA50, 92% (11/12; 95% exact CI: 62-100%) achieved PSA90, and 83% (10/12; 95% exact CI: 52-98%) had undetectable PSA levels.</p><p><strong>Conclusions: </strong>This study is the first to evaluate the effectiveness of rezvilutamide in patients with low-volume mHSPC. In a real-world clinical setting, the combination of rezvilutamide and ADT demonstrated favorable PSA response in this patient population. These findings provide additional treatment options for patients with low-volume mHSPC and support the need for further large-scale research on rezvilutamide in this subgroup.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 4","pages":"1119-1128"},"PeriodicalIF":1.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulator of cullins-1 predicts a poor prognosis and regulates epithelial-mesenchymal transition process through GSK-3β/Wnt signaling in renal cell carcinoma.","authors":"Qi Wu, Peng Li, Huijiang Zhang, Shengjie You, Zhaoyu Xu, Xiang Liu, Xuedong Chen, Weili Zhang, Xiaoqing Zhou","doi":"10.21037/tau-2024-646","DOIUrl":"https://doi.org/10.21037/tau-2024-646","url":null,"abstract":"<p><strong>Background: </strong>Renal cell carcinoma (RCC) exhibits malignant biological characteristics of cell invasion and metastasis. The role of regulator of cullins-1 (ROC1) in RCC is unknown. The present work focused on exploring ROC1's biological effect on RCC as well as clarifying its related mechanism.</p><p><strong>Methods: </strong>The messenger RNA (mRNA) expression of ROC1 in RCC tumor tissue and normal tissue was examined by reverse transcription-polymerase chain reaction (RT-PCR). We analyzed mRNA expression through RT-PCR, whereas protein level via western blot (WB) assay. We did some biological experiments in this study, including Cell Counting Kit-8 (CCK-8) assay, 5-ethynyl-2'-deoxyuridine (EdU) assay, Transwell invasion assay, and xenograft tumor assay.</p><p><strong>Results: </strong>ROC1 expression markedly increased in the RCC samples relative to healthy samples. ROC1 was related to the dismal outcome of RCC patients. We also found that the overexpression of ROC1 (oeROC1) promoted cell proliferation, epithelial-mesenchymal transition (EMT), and invasion, whereas ROC1 interference had opposite effects. ROC1 regulated GSK-3β/Wnt pathway within RCC cells. By constructing the RCC metastasis model in nude mice, it was found that ROC1 knockdown inhibited tumor metastasis, while shGSK-3β could reverse the effect of ROC1 knockdown.</p><p><strong>Conclusions: </strong>Collectively, our work preliminarily illuminated the tumor-promoting role of ROC1 in RCC and the potential molecular mechanism. Thus, our study may provide some evidence for the treatment of RCC.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 4","pages":"974-985"},"PeriodicalIF":1.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal role of immune cells in male infertility: a Mendelian randomization study.","authors":"Zilong Liang, Conglei Hu, Haofeng Pang, Yi Sha, Jizong Lv, Guanyu Wu, Haiyang Du, Liangliang Hao, Liping Yao, Fei Liu","doi":"10.21037/tau-2024-657","DOIUrl":"https://doi.org/10.21037/tau-2024-657","url":null,"abstract":"<p><strong>Background: </strong>Epidemiological studies have shown that early immune inflammatory responses are associated with male infertility, and bacteria and viruses interact with the host's immune and inflammatory systems through their unique structures. This study aims to use Mendelian randomization (MR) to investigate the causal relationship between different immune cell types and the risk of male infertility.</p><p><strong>Methods: </strong>Male infertility data was obtained from the FinnGen database, and immune cell subtypes data were gathered from the Genome-Wide Association Studies (GWAS) catalog. An MR analysis was performed to investigate the causal relationship between immune cells and male infertility. Several MR methods, including inverse-variance weighted (IVW), weighted median, weighted mode, MR-Egger, and simple mode, were employed. Reverse MR analysis was also conducted to explore the reverse causal relationship. Sensitivity analyses, including Cochran's Q test for heterogeneity, MR-Egger regression for pleiotropy, and MR-PRESSO to exclude pleiotropic outliers, were performed to assess the robustness of the findings.</p><p><strong>Results: </strong>The study identified 23 immune phenotypes causally associated with male infertility, of which six immune phenotypes were protective, and 17 were risk factors. No reverse causal relationship was found between male infertility and immune phenotypes in the reverse MR analysis.</p><p><strong>Conclusions: </strong>These results suggest that there is a potential causal relationship between some immune cell subtypes and male infertility at the genetic level.</p>","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"14 4","pages":"964-973"},"PeriodicalIF":1.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}